PND9 COST UTILITY ANALYSIS OF LEVODOPA-CARBIDOPA VS LEVODOPA-CARBIDOPA-ENTACAPONE IN PARKINSON DISEASE IN MEXICO

Autor:	E Rojas-Martínez, Matias Garcia-Constantino, Armando Nevárez-Sida, F Garcia-Contreras, G Del Angel-García, Patricia Constantino-Casas
Rok vydání:	2006
Předmět:	medicine.medical_specialty Cost–utility analysis business.industry Health Policy Public Health Environmental and Occupational Health medicine Levodopa carbidopa Urology Entacapone business medicine.drug
Zdroj:	Value in Health. 9:A376
ISSN:	1098-3015
DOI:	10.1016/s1098-3015(10)63742-4
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::018024e11d0bc1cfd7798b8a5400ecff https://doi.org/10.1016/s1098-3015(10)63742-4 Zobrazit plný text záznamu Full Text from ScienceDirect Plný text